In an open-label extension study of the cholinesterase inhibitor donepezil, Doody et al [7] concluded that donepezil was safe and effective for treating the symptoms of mild to moderate AD for up to 2 1/2 years. The gene discussed is BCHE; the disease is Alzheimer disease.